Do you want to read an article? Please log in or register.
Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial
Genitourinary CancerNuclear Medicine
COMMENTED
Related content
Genitourinary Cancer
Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial
Eur Urol
Armstrong AJ, Sartor O, de Bono J, Chi K, Fizazi K, Krause BJ, Herrmann K, Rahbar K, Tagawa ST, Saad F, Beer TM, Wu J, Mirante O, Morris MJ
doi: 10.1016/j.eururo.2024.08.021
COMMENTED
Genitourinary CancerNuclear Medicine
Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial)
★ 2
Recommended and commented by
Prof. Dr Ken Herrmann, Faculty Member
Radiology
Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, Fang B, Adra N, Garje R, Michalski JM, Chi K, de Bono J, Fizazi K, Krause B, Sartor O, Tagawa ST, Ghebremariam S, Brackman M, Wong CC, Catafau AM, Benson T, Armstrong AJ, Herrmann K
doi: 10.1148/radiol.233460
COMMENTED
Genitourinary CancerNuclear Medicine
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
★ 3
Recommended and commented by
Prof. Dr Ken Herrmann, Faculty Member
Lancet
Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, Crosby M, Piulats JM, Fléchon A, Wei XX, Mahammedi H, Roubaud G, Študentová H, Nagarajah J, Mellado B, Montesa-Pino Á, Kpamegan E, Ghebremariam S, Kreisl TN, Wilke C, Lehnhoff K, Sartor O, Fizazi K, PSMAfore Investigators
doi: 10.1016/S0140-6736(24)01653-2
CHICAGO 2025
Genitourinary Cancer
Earlier initiation of 177Lu-PSMA-617 is associated with improved clinical outcomes in patients with mCRPC in a real-world setting
CHICAGO 2025
Genitourinary Cancer
PSMA-delay castration: 177Lu-PSMA-617 versus observation in patients with PSMA-positive oligometastatic prostate cancer
COMMENTED
Genitourinary CancerNuclear Medicine
Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study
★ 3
Recommended and commented by
Prof. Dr Ken Herrmann, Faculty Member
Lancet Oncol
Azad AA, Bressel M, Tan H, Voskoboynik M, Suder A, Weickhardt AJ, Guminski A, Francis RJ, Saghebi J, Dhiantravan N, Joshua AM, Emmett L, Horvath L, Murphy DG, Hsiao E, Balakrishnar B, Lin P, Redfern A, Macdonald W, Ng S, Lee ST, Pattison DA, Nadebaum D, Kirkwood ID, Hofman MS, UpFrontPSMA Study Team
doi: 10.1016/S1470-2045(24)00440-6
CHICAGO 2025
Genitourinary Cancer
PRECISION: Real-world outcomes following guideline-recommended therapies after 177Lu-PSMA-617 in mCRPC
Nuclear Medicine
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
Lancet
Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, García-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D, all the NETTER-2 Trial Investigators
doi: 10.1016/S0140-6736(24)00701-3
COMMENTED
Genitourinary CancerNuclear Medicine
Efficacy and safety of rechallenge [177Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study)
★ 1
Recommended and commented by
Prof. Dr Ken Herrmann, Faculty Member
Eur J Nucl Med Mol Imaging
Rosar F, Schuler J, Burgard C, Blickle A, Bartholomä M, Maus S, Petto S, Khreish F, Schaefer A, Ezziddin S
doi: 10.1007/s00259-024-06825-4